1h Free Analyst Time
The publisher has been monitoring the dermatological drugs market and it is poised to grow by $19.33 bn during 2022-2026, accelerating at a CAGR of 14.67% during the forecast period. The report on the dermatological drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the need for safe and stable drugs that require minimal monitoring, the emergence of improved diagnostic modalities, and the need for affordable dermatological therapies.
The dermatological drugs market analysis includes the product segment and geographic landscape.
The dermatological drugs market is segmented as below:
By Product
- Biologics
- Small molecules
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the increase in prices of dermatological drugs as one of the prime reasons driving the dermatological drugs market growth during the next few years. Also, patent expiry of major drugs and availability of biologics/biosimilars for treatment will lead to sizable demand in the market.
The report on dermatological drugs market covers the following areas:
- Dermatological drugs market sizing
- Dermatological drugs market forecast
- Dermatological drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading dermatological drugs market vendors that include AbbVie, Amgen Inc., Bausch Health Companies Inc., Botanix Pharmaceutical, Bristol Myers Squibb Co., Cipla Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Johnson and Johnson, LEO Pharma AS, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Sol-Gel Technologies Ltd., Sun Pharmaceutical Industries Ltd., UCB SA, and Vibcare Pharma Pvt. Ltd. Also, the dermatological drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Product
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global dermatological drugs market: AbbVie, Amgen Inc., Bausch Health Companies Inc., Botanix Pharmaceutical, Bristol Myers Squibb Co., Cipla Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Johnson and Johnson, LEO Pharma AS, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Sol-Gel Technologies Ltd., Sun Pharmaceutical Industries Ltd., UCB SA, and Vibcare Pharma Pvt. Ltd.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is increase in prices of dermatological drugs.`
According to the report, one of the major drivers for this market is the need for safe and stable drugs that require minimal monitoring.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Amgen Inc.
- Bausch Health Companies Inc.
- Botanix Pharmaceutical
- Bristol Myers Squibb Co.
- Cipla Ltd.
- Dr. Reddys Laboratories Ltd.
- F. Hoffmann La Roche Ltd.
- Galderma SA
- GlaxoSmithKline Plc
- Johnson and Johnson
- LEO Pharma AS
- Lupin Ltd.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Sol-Gel Technologies Ltd.
- Sun Pharmaceutical Industries Ltd.
- UCB SA
- Vibcare Pharma Pvt. Ltd.